Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Naproxen
Stirlescent
Not routinely available
SMC (1154/16)
29/03/2023
Indication
Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
250mg effervescent tablets
Comments
-
Link to Advice
Advice Published
13/06/2016
SMC Submission Type
Abbreviated
SMC Status
Restricted